Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors-Reference-Cited by-同舟云学术

Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors

Published:2021-11-15 Issue: Volume: Page:
ISSN:0938-7994
Container-title:European Radiology
language:en
Short-container-title:Eur Radiol

Author:

Annovazzi Alessio^ORCID,Ferraresi Virginia,Rea Sandra,Russillo Michelangelo,Renna Davide,Carpano Silvia,Sciuto Rosa

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00330-021-08355-1.pdf

Reference28 articles.

1. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, ESMO Guidelines Committee (2019) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1884–1901. https://doi.org/10.1093/annonc/mdz411

2. Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193–201

3. Ugurel S, Röhmel J, Ascierto PA et al (2020) Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019. Eur J Cancer 130:126–138. https://doi.org/10.1016/j.ejca.2020.02.021

4. Robert C, Grob JJ, Stroyakovskiy D et al (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381:626–636. https://doi.org/10.1056/NEJMoa1904059

5. Bisschop C, de Heer EC, Brouwers AH, Hospers GAP, Jalving M (2020) Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: a systematic review. Crit Rev Oncol Hematol 153:103044. https://doi.org/10.1016/j.critrevonc.2020.103044

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review on radiomic analysis in 18F-fluorodeoxyglucose positron emission tomography for prediction of melanoma outcomes;Cancer Imaging;2024-07-05

2. Baseline and on Treatment Biodistribution Variability of 18F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication;Clinical Nuclear Medicine;2024-05-14

3. Prognostic Value of Baseline 18F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma Patients;Cancers;2023-12-26

4. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?;Clinical Nuclear Medicine;2023-12-19

5. PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy;European Journal of Surgical Oncology;2023-10